China strengthens its global pharmaceutical supply role, with FDF exports rising amid quality upgrades and international deals.
Licensing agreements featuring Chinese assets reached significant portions of global deals in 2025.
Key Developments
- Export Dominance: Major supplier of generic orals and injectables worldwide.
- Licensing Surge: Chinese innovative FDF in ~30-40% of out-licensing deals.
- Regulated Market Access: Growing approvals for complex generics/biosimilars in US/EU.
- Resilient Supply: Scale and pricing advantages maintain reliability despite diversification trends.
Supported by Made in China 2025, Chinese FDF are increasingly vital to global healthcare.